rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CRMD
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Oppenheimer lowers CorMedix stock price target to $13 on valuation
      Nov 13Investing.comCRMD
      CorMedix Inc. Q3 2026 Earnings Call Summary
      Nov 12Yahoo FinanceCRMD
      What CorMedix (CRMD) Said on Its Q3 Earnings Call
      Nov 12Yahoo FinanceCRMD
      Cormedix Q3 2026 Earnings Call Transcript
      Nov 12BenzingaCRMD
      CorMedix earnings missed by $0.09, revenue topped estimates
      Nov 12Investing.comCRMD
      CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
      Nov 12Yahoo FinanceCRMD
      CorMedix: Q3 Earnings Snapshot
      Nov 12Yahoo FinanceCRMD
      Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 12Yahoo FinanceCRMD
      CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
      Nov 10Yahoo FinanceCRMD
      Needham raises CorMedix stock price target on Heron acquisition
      Nov 10Investing.comCRMD
      CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings
      Nov 10Yahoo FinanceCRMDHRTX
      Why Heron Therapeutics Stock is Surging on Monday - Heron Therapeutics (NASDAQ:HRTX), Cormedix (NASDAQ:CR
      Nov 9BenzingaCRMDHRTX
      CorMedix stock gains as Heron deal adds four products
      Nov 9Investing.comCRMD
      CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
      Nov 9Yahoo FinanceCRMDHRTX
      CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
      Nov 6Yahoo FinanceCRMD
      Earnings Preview: CorMedix (CRMD) Q3 Earnings Expected to Decline
      Nov 4Yahoo FinanceCRMD
      CorMedix Reaffirms 2026 Revenue Guidance of $325 Million–$345 Million and Reports $355 Million Cash Position
      Nov 2Yahoo FinanceCRMD
      CorMedix reports $355M cash, reaffirms 2026 revenue guidance
      Nov 2Investing.comCRMD
      CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position
      Nov 2Yahoo FinanceCRMD
      CRMD Stock Hits Fresh 52-Week Low On DaVita’s Warning Of Sharp 2027 DefenCath Reimbursement Drop
      Oct 30Yahoo FinanceCRMDDVA
      Analysts Offer Insights on Healthcare Companies: Olympus (OtherOCPNF), IQVIA Holdings (IQV) and Cormedix (CRMD)

      Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.

      Oct 21The Globe and MailCRMD
      Cormedix Rezzayo label expansion under FDA review (CRMD:NASDAQ)
      Oct 19Seeking AlphaCRMD
      FDA accepts CorMedix filing for rezafungin fungal prophylaxis
      Oct 19Investing.comCRMD
      Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases

      PARSIPPANY, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) seeking approval of REZZAYO® (rezafungin for injection) for the prophylaxis of invasive fungal disease. The sNDA was submitted by Mundipharma, CorMedix’s global development partner, and the FDA has granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target ac

      Oct 19Yahoo FinanceCRMD
      Oppenheimer initiates CorMedix stock coverage with outperform rating
      Sep 23Investing.comCRMD
      Oppenheimer Initiates CorMedix at Outperform With $15 Price Target
      Sep 23Yahoo FinanceCRMD
      CorMedix at Wells Fargo 21st annual healthcare conference: growth, risk
      Sep 9Investing.comCRMDWFC
      CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged

      On August 13, CorMedix (NASDAQ:CRMD) reported second quarter revenue of $101.9 million, more than double what it posted a year earlier, alongside net income of $26 million and adjusted EBITDA of $58.7 million, nearly triple the prior year’s figure. Management also raised its full year adjusted EBITDA outlook. Yet full year revenue guidance stayed exactly […]

      Sep 8Yahoo FinanceCRMD
      Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet

      The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

      Sep 7Yahoo FinanceCRMD
      CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
      Sep 1Yahoo FinanceCRMDWFC
      CorMedix (CRMD) Upgraded to Buy: Here's Why

      CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

      Aug 31Yahoo FinanceCRMD

      This is the newest page. Registered accounts read further back.